<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159352</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-093</org_study_id>
    <nct_id>NCT02159352</nct_id>
  </id_info>
  <brief_title>Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants</brief_title>
  <official_title>A Phase 1 Clinical Study to Assess the Effect of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether multiple doses of darunavir/ritonavir or
      lopinavir/ritonavir affect the pharmacokinetics of daclatasvir in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <description>Cmax was obtained from concentration-time plot using a noncompartmental method and a validated pharmacokinetic analysis program.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <description>AUC(TAU) was the area under the curve from time zero to end of dosing interval. AUC(TAU) was obtained from concentration-time plot of daclatasvir using noncompartmental method and a validated pharmacokinetic analysis program.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <description>Tmax was obtained from concentration-time plot of daclatasvir by using non-compartmental method by a validated pharmacokinetic analysis program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <description>C24 was obtained from concentration time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <description>Cmax/D and C24/D are obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir</measure>
    <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
    <description>AUC(TAU)/D was obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days)</time_frame>
    <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Vital Sign Measurements</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
    <description>Criteria for abnormalities in vital sign measurements: Diastolic blood pressure: Value &gt;90 and change from baseline &gt; 0 or value &lt; 55 and change from baseline &lt;-10. Systolic blood pressure: Value &gt;140 and change from baseline &gt;20 or value &lt;90 and change from baseline &lt;-20. Heart rate: Value &gt;100 and change from baseline &gt;30 or value &lt;55 and change from baseline &lt;-15. Respiration: Value &gt;16 or change from baseline &gt;10. Temperature: Value &gt;38.3°C or change from baseline &gt;1.6°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
    <description>Abnormalities in ECG findings included: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, and second- or third-degree heart block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
    <description>Criteria for marked abnormalities in test results: Platelet count &gt;1.5*upper limits of normal (ULN) value, &gt;1.5*ULN if pretreatment (PreRx) value is missing, &lt;0.85*lower limit of normal (LLN) if PreRx ≥LLN, &lt;0.85*LLN if PreRx is missing, &lt;0.85*PreRx if PreRx &lt;LLN. Leukocytes &gt;1.2*ULN if LLN ≤PreRx ≤ULN, &gt;1.2*ULN if PreRx is missing, &gt;1.5*PreRx if PreRx &gt;ULN, &gt;ULN if PreRx &lt;LLN, &lt;0.85*PreRx if PreRx &lt;LLN, &lt;0.9*LLN if LLN ≤PreRx ≤ULN, &lt;0.9*LLN if PreRx is missing and &lt;LLN if PreRx &gt;ULN. Lymphocytes &gt;7.5*10^3 c/uL and &lt;0.75*10^3 c/uL. Neutrophils &lt;0.85*PreRx if PreRx &lt;1.5*ULN, &lt;1.5*ULN if PreRx ≥1.5*ULN and &lt;1.5*ULN if PreRx is missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results</measure>
    <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
    <description>Criteria for marked abnormalities on laboratory test results: urinary dipstick blood: ≥2 if pretreatment (PreRx) &lt;1, ≥2 if PreRx is missing or ≥2*PreRx if PreRx ≥1. Urinary microscopic red blood cell (RBC): ≥2 if PreRx &lt;2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Urinary microscopic white blood cell (WBC): ≥2 if PreRx &lt;2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Lactate dehydrogenase &gt;1.25*upper limit of normal (ULN) if PreRx ≤ULN, &gt;1.25*ULN if PreRx is missing and &gt;1.5*PreRx if PreRx &gt;ULN.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group 1: Daclatasvir and Darunavir/Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Daclatasvir oral tablet on specific days
Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Daclatasvir and Lopinavir/Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C: Daclatasvir oral tablet on specific days
Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <arm_group_label>Group 1: Daclatasvir and Darunavir/Ritonavir</arm_group_label>
    <arm_group_label>Group 2: Daclatasvir and Lopinavir/Ritonavir</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <arm_group_label>Group 1: Daclatasvir and Darunavir/Ritonavir</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>Group 1: Daclatasvir and Darunavir/Ritonavir</arm_group_label>
    <arm_group_label>Group 2: Daclatasvir and Lopinavir/Ritonavir</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <arm_group_label>Group 2: Daclatasvir and Lopinavir/Ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Key Inclusion Criteria:

          -  Healthy male and female participants, aged 18 to 49, as determined by medical history,
             physical examination, 12 lead electrocardiogram, vital signs, and clinical laboratory
             evaluations

        Key Exclusion Criteria:

          -  Any significant acute or chronic medical illness; donation of blood to a blood bank or
             in a clinical study (except a screening visit) within 4 weeks of study drug
             administration (within 2 weeks for plasma only); or blood screen findings positive for
             hepatitis C antibody, hepatitis B surface antigen, or HIV-1 and HIV-2 antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries, Llc D/B/A Icon Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <results_first_submitted>August 21, 2015</results_first_submitted>
  <results_first_submitted_qc>October 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2015</results_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 1 site in the United States of America.</recruitment_details>
      <pre_assignment_details>Of 49 participants enrolled, 28 were randomized to receive treatment. Of the 21 who were not randomized, 16 no longer met study criteria and 5 discontinued due to other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Daclatasvir + Darunavir/Ritonavir</title>
          <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4 and a 30-mg daclatasvir tablet once daily, along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
        </group>
        <group group_id="P2">
          <title>Daclatasvir + Lopinavir/Ritonavir</title>
          <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4 and a 30-mg daclatasvir tablet once daily, along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 1 (Day 1- 4)</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 2 (Day 5-14)</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daclatasvir + Darunavir/Ritonavir</title>
          <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4 and a 30-mg daclatasvir tablet once daily, along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
        </group>
        <group group_id="B2">
          <title>Daclatasvir + Lopinavir/Ritonavir</title>
          <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4 and a 30-mg daclatasvir tablet once daily, along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) for Daclatasvir</title>
        <description>Cmax was obtained from concentration-time plot using a noncompartmental method and a validated pharmacokinetic analysis program.</description>
        <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
        <population>All treated participants with adequate pharmacokinetic profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily, along with an 800-mg darunavir tablet, and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) for Daclatasvir</title>
          <description>Cmax was obtained from concentration-time plot using a noncompartmental method and a validated pharmacokinetic analysis program.</description>
          <population>All treated participants with adequate pharmacokinetic profiles.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1335" spread="38"/>
                    <measurement group_id="O2" value="493" spread="36"/>
                    <measurement group_id="O3" value="1412" spread="28"/>
                    <measurement group_id="O4" value="476" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A general linear mixed effect model (restricted maximum likelihood) with treatment as fixed effect and measurements within each participant as repeated measures was fitted to the log-transformed Cmax.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Geometric Mean Ratio</param_type>
            <param_value>0.384</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.348</ci_lower_limit>
            <ci_upper_limit>0.423</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A general linear mixed effect model (restricted maximum likelihood) with treatment as fixed effect and measurements within each participant as repeated measures was fitted to the log-transformed Cmax.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Geometric Mean Ratio</param_type>
            <param_value>0.337</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.306</ci_lower_limit>
            <ci_upper_limit>0.371</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir</title>
        <description>AUC(TAU) was the area under the curve from time zero to end of dosing interval. AUC(TAU) was obtained from concentration-time plot of daclatasvir using noncompartmental method and a validated pharmacokinetic analysis program.</description>
        <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
        <population>All treated participants with adequate pharmacokinetic profiles. Number of participants analyzed (N) signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclatasvir (60 mg) Days 1-4</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Daclatasvir (30 mg) + Darunavir/Ritonavir Days 5-14</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Daclatasvir (60 mg) Days 5-14</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O4">
            <title>Daclatasvir (30 mg) + Lopinavir/Ritonavir Days 5-14</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]) for Daclatasvir</title>
          <description>AUC(TAU) was the area under the curve from time zero to end of dosing interval. AUC(TAU) was obtained from concentration-time plot of daclatasvir using noncompartmental method and a validated pharmacokinetic analysis program.</description>
          <population>All treated participants with adequate pharmacokinetic profiles. Number of participants analyzed (N) signifies number of participants evaluable for this outcome measure.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12677" spread="41"/>
                    <measurement group_id="O2" value="8295" spread="39"/>
                    <measurement group_id="O3" value="13799" spread="26"/>
                    <measurement group_id="O4" value="7855" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A general linear mixed effect model (restricted maximum likelihood) with treatment as fixed effect and measurements within each participant as repeated measures was fitted to the log-transformed AUC(TAU).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Geometric Mean Ratio</param_type>
            <param_value>0.703</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.658</ci_lower_limit>
            <ci_upper_limit>0.750</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A general linear mixed effect model (restricted maximum likelihood) with treatment as fixed effect and measurements within each participant as repeated measures was fitted to the log-transformed AUC(TAU).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Geometric Mean Ratio</param_type>
            <param_value>0.577</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.535</ci_lower_limit>
            <ci_upper_limit>0.622</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir</title>
        <description>Tmax was obtained from concentration-time plot of daclatasvir by using non-compartmental method by a validated pharmacokinetic analysis program.</description>
        <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
        <population>All treated participants with adequate pharmacokinetic profile. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Plasma Concentration (Tmax) of Daclatasvir</title>
          <description>Tmax was obtained from concentration-time plot of daclatasvir by using non-compartmental method by a validated pharmacokinetic analysis program.</description>
          <population>All treated participants with adequate pharmacokinetic profile. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir</title>
        <description>C24 was obtained from concentration time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
        <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
        <population>All treated participants with adequate pharmacokinetic profile. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received 60 mg of daclatasvir tablet once daily from Day 1 through 4.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Observed at 24 Hours Postdose (C24) of Daclatasvir</title>
          <description>C24 was obtained from concentration time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
          <population>All treated participants with adequate pharmacokinetic profile. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225" spread="54"/>
                    <measurement group_id="O2" value="250" spread="45"/>
                    <measurement group_id="O3" value="225" spread="36"/>
                    <measurement group_id="O4" value="280" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir</title>
        <description>Cmax/D and C24/D are obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
        <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
        <population>All treated participants with adequate pharmacokinetic profile.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received 60 mg of daclatasvir tablet once daily from Day 1 through 4.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/ 50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Maximum Observed Plasma Concentration (Cmax/D) and Dose-normalized Plasma Concentration Observed at 24 Hours Postdose (C24/D) of Daclatasvir</title>
          <description>Cmax/D and C24/D are obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
          <population>All treated participants with adequate pharmacokinetic profile.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax/D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="38"/>
                    <measurement group_id="O2" value="16.4" spread="36"/>
                    <measurement group_id="O3" value="23.5" spread="28"/>
                    <measurement group_id="O4" value="15.9" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24/D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="54"/>
                    <measurement group_id="O2" value="8.34" spread="45"/>
                    <measurement group_id="O3" value="3.76" spread="36"/>
                    <measurement group_id="O4" value="9.33" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A general linear mixed effect model (restricted maximum likelihood) with treatment as fixed effect and measurements within each participant as repeated measures was fitted to the log-transformed Cmax/D.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Geometric Mean Ratio</param_type>
            <param_value>0.768</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.697</ci_lower_limit>
            <ci_upper_limit>0.846</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A general linear mixed effect model (restricted maximum likelihood) with treatment as fixed effect and measurements within each participant as repeated measures was fitted to the log-transformed Cmax/D.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Geometric Mean Ratio</param_type>
            <param_value>0.673</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.611</ci_lower_limit>
            <ci_upper_limit>0.742</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir</title>
        <description>AUC(TAU)/D was obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
        <time_frame>Predose (0 hour) on Day 2, 3 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 4 (Period 1); Predose (0 hour) on Day 12, 13 and 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hour on Day 14 (Period 2)</time_frame>
        <population>All treated participants with adequate pharmacokinetic profile. Here, N signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Area Under the Concentration-Time Curve in 1 Dosing Interval (AUC[TAU]/D) of Daclatasvir</title>
          <description>AUC(TAU)/D was obtained from concentration-time plot of daclatasvir by using noncompartmental method by a validated pharmacokinetic analysis program.</description>
          <population>All treated participants with adequate pharmacokinetic profile. Here, N signifies number of participants evaluable for this outcome measure.</population>
          <units>(ng*h/mL)/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211" spread="41"/>
                    <measurement group_id="O2" value="276" spread="39"/>
                    <measurement group_id="O3" value="230" spread="26"/>
                    <measurement group_id="O4" value="262" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A general linear mixed effect model (restricted maximum likelihood) with treatment as fixed effect and measurements within each participant as repeated measures was fitted to the log-transformed (AUC(TAU)/D).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Geometric Mean Ratio</param_type>
            <param_value>1.406</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.317</ci_lower_limit>
            <ci_upper_limit>1.501</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A general linear mixed effect model (restricted maximum likelihood) with treatment as fixed effect and measurements within each participant as repeated measures was fitted to the log-transformed (AUC(TAU)/D).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Geometric Mean Ratio</param_type>
            <param_value>1.154</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.070</ci_lower_limit>
            <ci_upper_limit>1.244</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</title>
        <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.</description>
        <time_frame>From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days)</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 -mg lopinavir/50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</title>
          <description>AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormalities in Vital Sign Measurements</title>
        <description>Criteria for abnormalities in vital sign measurements: Diastolic blood pressure: Value &gt;90 and change from baseline &gt; 0 or value &lt; 55 and change from baseline &lt;-10. Systolic blood pressure: Value &gt;140 and change from baseline &gt;20 or value &lt;90 and change from baseline &lt;-20. Heart rate: Value &gt;100 and change from baseline &gt;30 or value &lt;55 and change from baseline &lt;-15. Respiration: Value &gt;16 or change from baseline &gt;10. Temperature: Value &gt;38.3°C or change from baseline &gt;1.6°C.</description>
        <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
        <population>Participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir + Darunavir/Ritonavir</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4 and a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Daclatasvir + Lopinavir/Ritonavir</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4 and a 30-mg daclatasvir tablet once daily, along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormalities in Vital Sign Measurements</title>
          <description>Criteria for abnormalities in vital sign measurements: Diastolic blood pressure: Value &gt;90 and change from baseline &gt; 0 or value &lt; 55 and change from baseline &lt;-10. Systolic blood pressure: Value &gt;140 and change from baseline &gt;20 or value &lt;90 and change from baseline &lt;-20. Heart rate: Value &gt;100 and change from baseline &gt;30 or value &lt;55 and change from baseline &lt;-15. Respiration: Value &gt;16 or change from baseline &gt;10. Temperature: Value &gt;38.3°C or change from baseline &gt;1.6°C.</description>
          <population>Participants who received at least 1 dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings</title>
        <description>Abnormalities in ECG findings included: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, and second- or third-degree heart block.</description>
        <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/ 50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings</title>
          <description>Abnormalities in ECG findings included: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, and second- or third-degree heart block.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR &gt;210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS &gt;120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT &gt;500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF &gt;450</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results</title>
        <description>Criteria for marked abnormalities in test results: Platelet count &gt;1.5*upper limits of normal (ULN) value, &gt;1.5*ULN if pretreatment (PreRx) value is missing, &lt;0.85*lower limit of normal (LLN) if PreRx ≥LLN, &lt;0.85*LLN if PreRx is missing, &lt;0.85*PreRx if PreRx &lt;LLN. Leukocytes &gt;1.2*ULN if LLN ≤PreRx ≤ULN, &gt;1.2*ULN if PreRx is missing, &gt;1.5*PreRx if PreRx &gt;ULN, &gt;ULN if PreRx &lt;LLN, &lt;0.85*PreRx if PreRx &lt;LLN, &lt;0.9*LLN if LLN ≤PreRx ≤ULN, &lt;0.9*LLN if PreRx is missing and &lt;LLN if PreRx &gt;ULN. Lymphocytes &gt;7.5*10^3 c/uL and &lt;0.75*10^3 c/uL. Neutrophils &lt;0.85*PreRx if PreRx &lt;1.5*ULN, &lt;1.5*ULN if PreRx ≥1.5*ULN and &lt;1.5*ULN if PreRx is missing.</description>
        <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/ 50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Abnormalities in Hematology Laboratory Test Results</title>
          <description>Criteria for marked abnormalities in test results: Platelet count &gt;1.5*upper limits of normal (ULN) value, &gt;1.5*ULN if pretreatment (PreRx) value is missing, &lt;0.85*lower limit of normal (LLN) if PreRx ≥LLN, &lt;0.85*LLN if PreRx is missing, &lt;0.85*PreRx if PreRx &lt;LLN. Leukocytes &gt;1.2*ULN if LLN ≤PreRx ≤ULN, &gt;1.2*ULN if PreRx is missing, &gt;1.5*PreRx if PreRx &gt;ULN, &gt;ULN if PreRx &lt;LLN, &lt;0.85*PreRx if PreRx &lt;LLN, &lt;0.9*LLN if LLN ≤PreRx ≤ULN, &lt;0.9*LLN if PreRx is missing and &lt;LLN if PreRx &gt;ULN. Lymphocytes &gt;7.5*10^3 c/uL and &lt;0.75*10^3 c/uL. Neutrophils &lt;0.85*PreRx if PreRx &lt;1.5*ULN, &lt;1.5*ULN if PreRx ≥1.5*ULN and &lt;1.5*ULN if PreRx is missing.</description>
          <population>All treated participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results</title>
        <description>Criteria for marked abnormalities on laboratory test results: urinary dipstick blood: ≥2 if pretreatment (PreRx) &lt;1, ≥2 if PreRx is missing or ≥2*PreRx if PreRx ≥1. Urinary microscopic red blood cell (RBC): ≥2 if PreRx &lt;2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Urinary microscopic white blood cell (WBC): ≥2 if PreRx &lt;2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Lactate dehydrogenase &gt;1.25*upper limit of normal (ULN) if PreRx ≤ULN, &gt;1.25*ULN if PreRx is missing and &gt;1.5*PreRx if PreRx &gt;ULN.</description>
        <time_frame>From start of study treatment (Day 1) to study discharge (up to 15 days)</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg ritonavir capsule once daily on Days 5 through 14.</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Daclatasvir (60 mg)</title>
            <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
          </group>
          <group group_id="O4">
            <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
            <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormalities in Urinalysis and Other Chemistry Testing Results</title>
          <description>Criteria for marked abnormalities on laboratory test results: urinary dipstick blood: ≥2 if pretreatment (PreRx) &lt;1, ≥2 if PreRx is missing or ≥2*PreRx if PreRx ≥1. Urinary microscopic red blood cell (RBC): ≥2 if PreRx &lt;2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Urinary microscopic white blood cell (WBC): ≥2 if PreRx &lt;2, ≥2 if PreRx is missing or ≥4 if PreRx ≥2. Lactate dehydrogenase &gt;1.25*upper limit of normal (ULN) if PreRx ≤ULN, &gt;1.25*ULN if PreRx is missing and &gt;1.5*PreRx if PreRx &gt;ULN.</description>
          <population>All treated participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood, urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study treatment (Day 1) to study discharge for AEs (up to 15 days); Day 1 to 30 days after last dose of study treatment for SAEs (up to 44 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Total</title>
          <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4 and 30 mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg of ritonavir capsule once daily on Days 5 through 14.</description>
        </group>
        <group group_id="E2">
          <title>Group 1: Daclatasvir (60 mg)</title>
          <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
        </group>
        <group group_id="E3">
          <title>Group 1: Daclatasvir (30 mg) + Darunavir/Ritonavir</title>
          <description>Participants received a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100-mg of ritonavir capsule once daily on Days 5 through 14.</description>
        </group>
        <group group_id="E4">
          <title>Group 2: Total</title>
          <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4 and a 30-mg daclatasvir tablet once daily along with an 800-mg darunavir tablet and a 100­-mg ritonavir capsule once daily on Days 5 through 14.</description>
        </group>
        <group group_id="E5">
          <title>Group 2: Daclatasvir (60 mg)</title>
          <description>Participants received a 60-mg daclatasvir tablet once daily on Days 1 through 4.</description>
        </group>
        <group group_id="E6">
          <title>Group 2: Daclatasvir (30 mg) + Lopinavir/Ritonavir</title>
          <description>Participants received a 30-mg daclatasvir tablet once daily along with 2 200-mg lopinavir/ 50-mg ritonavir tablets twice daily on Days 5 through 14.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram PR prolongation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial’s primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

